Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Is there an optimal sequence of biologic therapies for inflammatory bowel disease?
Brian Bressler
Therapeutic Advances in Gastroenterology (2023) Vol. 16
Open Access | Times Cited: 22

Showing 22 citing articles:

Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development
Tsvetelina Velikova, Metodija Sekulovski, Monika Peshevska-Sekulovska
Antibodies (2024) Vol. 13, Iss. 1, pp. 16-16
Open Access | Times Cited: 8
Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis
Ashwin N. Ananthakrishnan, M. Hassan Murad, Frank I. Scott, et al.
Gastroenterology (2024) Vol. 167, Iss. 7, pp. 1460-1482
Closed Access | Times Cited: 5
Relationship Between Patient Demographics and Biologic Therapy Use in Inflammatory Bowel Disease. A Single Center Cross‐Sectional Study
Mohammad Shehab, Abdulwahab Alsayegh, Munirah Alabdulhadi, et al.
JGH Open (2025) Vol. 9, Iss. 1
Open Access
Relapse Rates and Predictors for Relapse in Ulcerative Colitis and Crohn’s Disease Patients After Discontinuation of Vedolizumab or Ustekinumab: The REVEUS Study
A Massano, Edoardo Savarino, Simone Saibeni, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 1793-1793
Open Access
Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study
Tatsunori Goto, Hiroshi Okamura, Takashi Ikeda, et al.
International Journal of Hematology (2025)
Open Access
Novel Small Molecules in IBD: Current State and Future Perspectives
André Jefremow, Markus F. Neurath
Cells (2023) Vol. 12, Iss. 13, pp. 1730-1730
Open Access | Times Cited: 12
Research progress of Ustekinumab in the treatment of inflammatory bowel disease
Weilin Zhang, Guoqiang Zhong, Xingxing Ren, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Timing of first abdominal operation in Crohn’s disease based on a diagnostic model
Lichao Yang, Yawei Zhang, Baojia Yao, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY
Noa Krugliak Cleveland, Sabyasachi Ghosh, Benjamin Chastek, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 10, pp. 1776-1787
Open Access | Times Cited: 7
Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn’s disease patients: a retrospective multicenter study
Ji Eun Na, Yong Eun Park, Jongha Park, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
A molecular subtyping associated with the cGAS-STING pathway provides novel perspectives on the treatment of ulcerative colitis
Chen Wang, Xin Gao, Yanchen Li, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Co-occurrence of oral pemphigus vulgaris and herpes simplex virus infection in a young patient with Crohn’s disease: report of a rare case of oral lesions during anti-TFN alpha and immunomodulator therapy
Danielle Nobre Lopes, Noêmia Pereira de Oliveira, Karla Cristina de Campos Augusto, et al.
International Journal of Colorectal Disease (2024) Vol. 39, Iss. 1
Open Access | Times Cited: 1
Prediction of the Short-Term Effectiveness of Ustekinumab in Patients with Moderate to Severe Crohn’s Disease
Tao Su, Ling Liu, Meng Fan, et al.
Journal of Inflammation Research (2024) Vol. Volume 17, pp. 9181-9191
Open Access | Times Cited: 1
Primary Sclerosing Cholangitis: Gender Effects in Valencia’s Low-Prevalence Region
Alejandro Mínguez, Isabel Conde, Cristina Montón, et al.
Digestive Diseases and Sciences (2024) Vol. 69, Iss. 5, pp. 1863-1871
Closed Access
New Ustekinumab Biosimilar Candidate FYB202: Pharmacokinetic Equivalence Demonstrated in a Randomized, Double‐Blind, Parallel‐Group, Single‐Dose Trial in Healthy Subjects
Sigrid Balser, Katrin Nopora, J. Körner, et al.
Clinical Pharmacology in Drug Development (2024)
Open Access
Mirikizumab in moderately to severely active ulcerative colitis: a profile of its use
Simon Fung, Hannah A. Blair
Drugs & Therapy Perspectives (2024) Vol. 40, Iss. 11, pp. 433-443
Closed Access
Effectiveness and Treatment Persistence of Vedolizumab Compared to Anti‐Tumour Necrosis Factor‐α in Patients With Crohn's Disease: A Systematic Literature Review and Meta‐Analysis
Alessandro Armuzzi, Séverine Vermeire, María Chaparro, et al.
United European Gastroenterology Journal (2024)
Open Access
Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy
Jonathan Salcedo, Daniel Hill‐McManus, Chloë Hardern, et al.
PharmacoEconomics - Open (2024)
Open Access
The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study
Patrick Gagnon‐Sanschagrin, Myrlene Sanon, M. Davidson, et al.
Journal of Medical Economics (2024) Vol. 27, Iss. 1, pp. 931-940
Open Access
Therapeutic options for children and young people with moderate-to-severe ulcerative colitis
James J. Ashton, Kwang Yang Lee, Anthi Thangarajah, et al.
Frontline Gastroenterology (2024) Vol. 15, Iss. 5, pp. 387-394
Closed Access
Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY
Noa Krugliak Cleveland, Sabyasachi Ghosh, Benjamin Chastek, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access
A Practical Guide to the Use of Mirikizumab
Edward L. Barnes
The American Journal of Gastroenterology (2023) Vol. 119, Iss. 3, pp. 400-403
Closed Access | Times Cited: 1
Page 1

Scroll to top